Potassium phosphate 17.42% (potassium 10mmol/5ml) solution for infusion 5ml ampoules
Monopotassium phosphate, MKP, (also potassium dihydrogenphosphate, KDP, or monobasic potassium phosphate), KH2PO4, is a soluble salt of potassium and the dihydrogen phosphate ion.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Potassium phosphate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Potassium phosphate
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Potassium phosphate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
MHRA licensed products
View all licensed products for Potassium phosphate on the MHRA register
Potassium phosphate 17.42% (potassium 10mmol/5ml) solution for infusion 5ml ampoules
Martindale Pharmaceuticals Ltd
Potassium phosphate 17.42% (potassium 10mmol/5ml) solution for infusion 5ml ampoules
Therapeutically similar medicines
Oral liquids
(1)Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(11)
Neonatal parenteral nutrition (NG154)
Chronic kidney disease: assessment and management (NG203)
Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (CG32)
Renal and ureteric stones: assessment and management (NG118)
Endoscopic carbon dioxide laser cricopharyngeal myotomy for relief of oropharyngeal dysphagia (HTG406)
Renal replacement therapy and conservative management (NG107)
Constipation in children and young people: diagnosis and management (CG99)
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)
Type 1 diabetes in adults: diagnosis and management (NG17)
COVID-19 rapid guideline: managing COVID-19 (NG191)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 5 · Randomised trials: 3 · 1946–2026
Showing the 50 most relevant studies, sorted by most relevant.
Franczyk B, Rysz J, Gluba-Sagr A
2026
L. Mo, Liming Lv, Min Deng, et al.
Cement and Concrete Research, 2018
Biwan Xu, B. Lothenbach, A. Leemann, et al.
Cement and Concrete Research, 2018
A. Naveed, Huijun Yang, Jun Yang, et al.
Angewandte Chemie, 2019
H. Han, Supanjani, K. Lee
Plant Soil and Environment, 2018
M. L. Rouzic, T. Chaussadent, L. Stefan, et al.
Cement and Concrete Research, 2017
Biwan Xu, Biwan Xu, Hongyan Ma, et al.
Cement and Concrete Research, 2017
Dengdeng Zheng, Tao Ji, Canqiang Wang, et al.
Construction and Building Materials, 2016
Biwan Xu, F. Winnefeld, J. Kaufmann, et al.
Cement and Concrete Research, 2019
Calabrese V, Tripepi GL, Santoro D, et al.
2026
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
4.8 to 10.6 hours
Mechanism
hosphorus has a number of important functions in the biochemistry of the body.
Food interactions
3 warnings
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
4.8 to 10.6 hours
Protein binding
Volume of distribution
Elimination
90%
Potassium is excreted mainly by the kidneys.…
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Used as a nutritional supplement in foods, a nonlinear optical material for laser use, and in wastewater treatment;
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 668 interactions
Rat : LdLo : 4640mg/kg (Oral)
Phosphate is a major intracellular anion that participates in providing energy for metabolism of substrates and contributes to important metabolic and enzymatic reactions in almost all organs and tissues. Phosphate exerts a modifying influence on calcium concentrations, a buffering effect on acid-base equilibrium, and has a major role in the renal excretion of hydrogen ions.
How the body processes this drug — absorption, distribution, metabolism, and elimination
Potassium is excreted mainly by the kidneys. Small amounts of potassium may be excreted via the skin and intestinal tract, but most of the potassium excreted into the intestine is later reabsorbed.
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Monopotassium phosphate
Matched from: Potassium phosphate
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72